Latest 10-Q quarterly reports

AmBase Corporation's Q2 2026 report highlights persistent operating losses, substantial doubt regarding its ability to continue as a going concern, and ongoing complex litigation.

The Bitwise Avalanche ETF experienced a substantial unrealized depreciation in its Avalanche holdings during the second quarter of 2026, impacting overall net assets.

The Bitwise XRP ETF reported a net decrease in net assets resulting from operations of $84,915 thousand for the three months ended June 30, 2026, primarily due to unrealized losses on its XRP holdings.

The Bitwise Chainlink ETF (CLNK) reported a significant decrease in its Net Asset Value (NAV) per share for the quarter ended June 30, 2026, primarily driven by unrealized losses on its Chainlink holdings.

The Bitwise Dogecoin ETF experienced a substantial decrease in net assets during the first six months of 2026, primarily driven by the depreciation of its Dogecoin holdings.

The Bitwise Hyperliquid ETF (BHYP) has reported a significant increase in Net Asset Value (NAV) per share since its commencement of operations on May 14, 2026, reaching $36.75 by June 30, 2026, up from $25.00.

UTG, Inc. announced a substantial increase in net income for the second quarter and first half of 2026, largely driven by significant realized investment gains and favorable changes in equity security valuations.

Landmark Bancorp, Inc. announced a 22.4% increase in net earnings for the second quarter of 2026 compared to the prior year, driven by higher net interest income.

Canterbury Park Holding Corporation announced Q2 2026 results showing revenue growth and a significant increase in Adjusted EBITDA, though a net loss was reported due to an impairment charge.

Steele Bancorp, Inc. announced significant increases in net income and key financial metrics for the second quarter of 2026, driven by the successful integration of its Northumberland Bancorp acquisition.

Leapfrog Acquisition Corporation reports on its financial condition for the quarter ended June 30, 2026, highlighting its status as a SPAC with substantial trust account funds and ongoing efforts to identify a business combination target.

The Cannaisseur Group, Inc. filed its Q2 2026 10-Q, revealing no revenue, a growing deficit, and significant going concern issues, despite a pending acquisition.

BV Financial, Inc. reported its Q2 2026 results, showing a slight decrease in total assets and loans, but maintaining strong capital ratios and improved net interest margin.

Juniata Valley Financial Corp. announced a significant increase in net income for the second quarter of 2026, driven by robust net interest income and improved asset yields.

Universal Token, Inc. reported continued net losses and a going concern warning in its Q2 2026 Form 10-Q, with no revenue generated and significant software development costs.

Table Trac, Inc. announced a significant increase in revenue and net income for the second quarter of 2026, driven by system sales and strong operational performance.

Invech Holdings, Inc. filed its Q2 2026 report, revealing no revenue, a substantial net loss of $202,739 for the six months ended June 30, 2026, and significant concerns about its ability to continue as a going concern.

CareView Communications, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting increased revenues but highlighting a material weakness in internal controls and substantial doubt about its ability to continue as a going concern.

BETA Technologies, Inc. filed its Q2 2026 Form 10-Q, detailing increased revenues in service but also substantial operating losses and R&D investments.

Monopar Therapeutics Inc. files its Q2 2026 Form 10-Q, detailing progress on ALXN1840 for Wilson disease, including near completion of its NDA rolling submission, and advancements in its radiopharmaceutical pipeline.

Nucor Corporation announced robust financial results for the second quarter and first six months of 2026, showcasing substantial increases in net sales and net earnings compared to the prior year.

Neonode Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting a decrease in total revenues driven by lower non-recurring engineering income, though license fees saw an increase.

Spruce Biosciences, Inc. filed its Form 10-Q for the period ending June 30, 2026, detailing continued net losses and a focus on advancing its TA-ERT therapy for MPS IIIB, while highlighting the need for substantial additional financing.

Cardiff Lexington Corporation's Q2 2026 Form 10-Q reveals a significant increase in net loss to $2.48 million, driven by declining revenues and rising operating expenses.

Dyadic International reported a net loss of $2.12 million for Q2 2026, with significant concerns remaining about its ability to continue as a going concern.

Aprea Therapeutics reports continued net losses and cash burn, with funding expected to last into Q1 2028, while advancing its APR-1051 clinical program.

QHSLab, Inc. filed its Q2 2026 10-Q, showing increased revenues driven by its Integrated Service Program, but continued operating losses and a going concern warning.

flyExclusive, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting a 15.6% increase in revenue to $207.5 million for the first six months, but also highlighting continued net losses and a substantial accumulated deficit.

Avalyn Pharma Inc. details progress in its Phase 2b clinical trial for AP01 and Phase 2 trial for AP02, alongside a robust cash position post-IPO, while acknowledging ongoing development risks.

B&G Foods, Inc. reported a net loss for the period ended July 4, 2026, with a significant decrease in net sales driven by divestitures and base business declines, alongside increased interest expenses.